Avenue Therapeutics (NASDAQ:ATXI) Trading 20.6% Higher – Should You Buy?

Avenue Therapeutics, Inc. (NASDAQ:ATXI)’s share price was up 20.6% during mid-day trading on Thursday . The stock traded as high as $0.3256 and last traded at $0.3256. 686 shares changed hands during trading, a decline of 88% from the average daily volume of 5,944 shares. The stock had previously closed at $0.27.

Avenue Therapeutics Stock Performance

The firm has a market cap of $1.07 million, a P/E ratio of 0.02 and a beta of -0.21. The company has a 50 day moving average of $0.40 and a 200 day moving average of $0.42.

About Avenue Therapeutics

Avenue Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for disorders of the central nervous system, with an initial emphasis on acute pain management. The company’s research and development efforts are centered on reformulating established active pharmaceutical ingredients to address unmet needs in hospital and outpatient settings, aiming to improve safety profiles, reduce opioid exposure and support enhanced patient recovery.

The company’s lead product candidate is intravenous tramadol, a unique non-solicited opioid analgesic that combines dual mechanisms of action to manage moderate to severe acute pain.